No profile data available.
Beta Bionics, Inc. (BBNX) is a healthcare company in the IV treatment equipment industry, based in Irvine, United States, with about 420 full-time employees.
It reported revenue of $100.25 million for fiscal year 2025, up 53.9% from fiscal year 2024, and net income of -$73.20 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $32.01 million, up 37.8% from a year before. Its market capitalization was $951.07 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Beta Bionics reported $100.25 million in revenue for fiscal year 2025, up 53.9% from $65.12 million in fiscal year 2024. In Q2 2026 revenue was $32.01 million.
$951.07 million as of October 9, 2026.
Listed companies of a similar size in the same industry (IV treatment equipment) include ICU Medical, Inc. (ICUI), Tandem Diabetes Care, Inc. (TNDM), Iradimed Corporation (IRMD), CorMedix Inc. (CRMD).